Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23035IDB-L5

Select Item

Empower your strategies with our Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions.

Squamous cell carcinoma is a subtype of non-small cell lung cancer (NSCLC) originating in the squamous cells lining the airways. It constitutes about 25-30% of all lung cancers. Linked to smoking, symptoms include persistent cough, chest pain, and breathing difficulties. Diagnosis involves imaging, biopsy, and staging to determine the cancer’s extent. Treatment options depend on the stage but may include surgery, chemotherapy, radiation therapy, or targeted therapies. Prognosis varies based on factors like stage and overall health. Research continues to explore new therapies and personalized approaches for improved outcomes in squamous NSCLC patients.

The Squamous Non-Small Cell Lung Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Squamous Non-Small Cell Lung Cancer and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Squamous Non-Small Cell Lung Cancer
Key Targets
· Programmed Cell Death Protein 1; Programmed Cell Death 1 Ligand 1; Epidermal Growth Factor Receptor ERB1; T Cell Immunoreceptor With Ig And ITIM Domains; Cytotoxic T Lymphocyte Protein 4; Lymphocyte Activation Gene 3 Protein; Fibroblast Growth Factor Receptor 3; Poly [ADP Ribose] Polymerase 2; Poly [ADP Ribose] Polymerase 1; and Fibroblast Growth Factor Receptor 1
Key Mechanisms of Action
· Programmed Cell Death Protein 1 Antagonist; Programmed Cell Death 1 Ligand 1 Inhibitor; T Cell Immunoreceptor With Ig And ITIM Domains Antagonist; Lymphocyte Activation Gene 3 Protein Inhibitor; Epidermal Growth Factor Receptor ERB1 Antagonist; Cytotoxic T Lymphocyte Protein 4 Antagonist; Fibroblast Growth Factor Receptor 1 Inhibitor; Fibroblast Growth Factor Receptor 2 Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; and Poly [ADP Ribose] Polymerase 1 Inhibitor
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Intravenous Drip; Parenteral; Intramuscular; Intraperitoneal; Intravesical; Intratumor; and Intrathecal
Key Molecule Types
· Monoclonal Antibody; Small Molecule; Monoclonal Antibody Conjugated; Fusion Protein; Cell Therapy; Gene-Modified Cell Therapy; Subunit Vaccine; Recombinant Vector Vaccine; mRNA Vaccine; and Oncolytic Virus
Major Companies
· BeiGene Ltd; F. Hoffmann-La Roche Ltd; Merck & Co Inc; GSK plc; AstraZeneca Plc; Bristol-Myers Squibb Co; Shanghai Henlius Biotech Inc; Pfizer Inc; Tango Therapeutics Inc; and Zai Lab Ltd

Scope

  • Therapeutics in Development: Covering 149 molecules, with 145 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Squamous Non-Small Cell Lung Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Squamous Non-Small Cell Lung Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Squamous Non-Small Cell Lung Cancer treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
AbelZeta Inc
Ability Pharmaceuticals SL
Adaptimmune Therapeutics Plc
Adlai Nortye Biopharma Co Ltd
Akamis Bio Ltd
Akeso Inc
Alphamab Oncology
Amgen Inc
AP Biosciences Inc
Arcus Biosciences Inc
Astellas Pharma Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Ayala Pharmaceuticals Inc.
Barinthus Biotherapeutics Plc
Bayer AG
BeiGene Ltd
Bicara Therapeutics Inc
Bicycle Therapeutics Plc
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cantargia AB
CDR-Life Inc
Celltrion Inc
Celon Pharma SA
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cincinnati Children's Hospital Medical Center
CorriXR Therapeutics Inc
CStone Pharmaceuticals Co Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Dyadic International Inc
Eikon Therapeutics Inc
Eli Lilly and Co
Evaxion Biotech A/S
F. Hoffmann-La Roche Ltd
f5 Therapeutics Inc
Forbius
Genentech USA Inc
Genmab AS
GSK plc
Guangzhou Sinogen Pharmaceutical Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Ideaya Biosciences Inc
Immatics NV
Immunitas Therapeutics Inc
ImmunityBio Inc
Imugene Ltd
Incyte Corp
Innovent Biologics Inc
iTeos Therapeutics Inc
Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KAHR medical Ltd
Kura Oncology Inc
Laboratoires Pierre Fabre SA
Leap Therapeutics Inc
LIfT BioSciences Ltd
MacroGenics Inc
Medicenna Therapeutics Corp
Merck & Co Inc
Merck KGaA
Merus NV
Mirati Therapeutics Inc
Moderna Inc
Mythic Therapeutics Inc
Nouscom AG
Novartis AG
Onconova Therapeutics Inc
Palo BioFarma SL
Pan Cancer T BV
PDC Line Pharma SAS
PharmAbcine Inc
ProLynx LLC
Promontory Therapeutics Inc
Qilu Puget Sound Biotherapeutics Corp
Rain Oncology Inc
Regeneron Pharmaceuticals Inc
Sanofi
SciClone Pharmaceuticals Holdings Ltd
Seagen Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
SignalChem Lifesciences Corp
Standigm Inc
Summit Therapeutics Inc
Sunho (China) Biopharmaceutical Co Ltd
Synermore Biologics Co Ltd
Systimmune Inc
Taiho Oncology Inc
Takeda Pharmaceutical Co Ltd
Tango Therapeutics Inc
UNC Lineberger Comprehensive Cancer Center
University of Pittsburgh
University of Tubingen
VM Discovery Inc
Volastra Therapeutics Inc
Zai Lab Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Squamous Non-Small Cell Lung Cancer reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 in real time.

  • Access a live Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more